McCarthy, Deirdre M.
Lowe, Sarah E.
Morgan, Thomas J.
Cannon, Elisa N.
Biederman, Joseph
Spencer, Thomas J.
Bhide, Pradeep G.
Funding for this research was provided by:
National Institutes of Health (R15 DA043848)
Florida State University (Jim and Betty Anne Rodgers Chair Fund)
Article History
Received: 8 March 2020
Accepted: 30 June 2020
First Online: 20 July 2020
Competing interests
: Deirdre McCarthy has financial interest in Avekshan, LLC, which is disclosed to and is managed by the Florida State University Research Foundation. She is an inventor of following intellectual property through Florida State University: US Patent (#10,245,271 B2) and a pending US patent application 16/369,748. Thomas Morgan, Sarah Lowe and Elisa Cannon have no competing financial interest. Joseph Biederman is currently receiving research support from the following sources: AACAP, Feinstein Institute for Medical Research, Food and Drug Administration, Genentech, Headspace Inc., NIDA, Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., Tris, and NIH. Dr. Biederman’s research program has received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Bracket Global, Ingenix, Prophase, Shire, Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at the Massachusetts General Hospital (MGH). In 2020 through MGH corporate licensing, Dr. Biederman has a US Patent (#14/027,676) for a non-stimulant treatment for ADHD, a US Patent (#10,245,271 B2) on a treatment of impaired cognitive flexibility, and a patent pending (#61/233,686) on a method to prevent stimulant abuse. He receives honoraria from the MGH Psychiatry Academy for tuition-funded CME courses. In 2019, he was a consultant for Akili, Avekshan, Jazz Pharma, and Shire/Takeda. He received research support from Lundbeck AS and Neurocentria Inc. Through MGH CTNI, he participated in a scientific advisory board for Supernus. He received honoraria from the MGH Psychiatry Academy for tuition-funded CME courses. Thomas J Spencer has, in the last three years, received research support or was a consultant from the following sources: Avekshan, Lundbeck, Sunovion, the FDA and the Department of Defense. Consultant fees are paid to the MGH Clinical Trials Network and not directly to Dr. Spencer. Dr. Spencer received support from Royalties and Licensing fees on copyrighted ADHD scales through MGH Corporate Sponsored Research and Licensing. Through MGH corporate licensing, Dr. Spencer has a US Patent (#14/027,676) for a non-stimulant treatment for ADHD and a patent pending (#61/233,686) for a method to prevent stimulant abuse. Pradeep Bhide has financial interest in Avekshan, LLC, which is disclosed to and is managed by the Florida State University Research Foundation. He is an inventor of following intellectual property through Florida State University: US patents 14/027,676) and 10,245,271 B2) and pending applications, 61/233,686 and 16/369,748.